Experimental murine invasive pulmonary aspergillosis

D. J. Eisenstein, Paul Williams Biddinger, J. C. Rhodes

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A new model of invasive pulmonary aspergillosis (IPA) was developed in immunosuppressed mice. Intranasal route of inoculation was used to deliver predictable numbers of Aspergillus flavus conidia. The LD50 was determined to be 2.7 x 102 viable conidia, and a combination of quantitative culture and determination of chitin content was shown to best measure the progression of pulmonary disease. The evolution of IPA in these mice conformed with what has been reported in human cases of aspergillosis; both histopathology of the pulmonary lesions and dissemination pattern resembled their human counterparts. The authors hope to use this model to study virulence mechanisms of Aspergillus and novel therapeutic methods.

Original languageEnglish (US)
Pages (from-to)510-515
Number of pages6
JournalAmerican Journal of Clinical Pathology
Volume93
Issue number4
DOIs
StatePublished - Jan 1 1990

Fingerprint

Invasive Pulmonary Aspergillosis
Fungal Spores
Aspergillus flavus
Chitin
Aspergillosis
Lethal Dose 50
Aspergillus
Lung Diseases
Virulence
Lung
Therapeutics

Keywords

  • Aspergillosis
  • Histopathology
  • Intranasal inoculations
  • LD50
  • Murine model

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Experimental murine invasive pulmonary aspergillosis. / Eisenstein, D. J.; Biddinger, Paul Williams; Rhodes, J. C.

In: American Journal of Clinical Pathology, Vol. 93, No. 4, 01.01.1990, p. 510-515.

Research output: Contribution to journalArticle

Eisenstein, D. J. ; Biddinger, Paul Williams ; Rhodes, J. C. / Experimental murine invasive pulmonary aspergillosis. In: American Journal of Clinical Pathology. 1990 ; Vol. 93, No. 4. pp. 510-515.
@article{0893eb5ea6f44d8b9a29e51cccf4f96f,
title = "Experimental murine invasive pulmonary aspergillosis",
abstract = "A new model of invasive pulmonary aspergillosis (IPA) was developed in immunosuppressed mice. Intranasal route of inoculation was used to deliver predictable numbers of Aspergillus flavus conidia. The LD50 was determined to be 2.7 x 102 viable conidia, and a combination of quantitative culture and determination of chitin content was shown to best measure the progression of pulmonary disease. The evolution of IPA in these mice conformed with what has been reported in human cases of aspergillosis; both histopathology of the pulmonary lesions and dissemination pattern resembled their human counterparts. The authors hope to use this model to study virulence mechanisms of Aspergillus and novel therapeutic methods.",
keywords = "Aspergillosis, Histopathology, Intranasal inoculations, LD50, Murine model",
author = "Eisenstein, {D. J.} and Biddinger, {Paul Williams} and Rhodes, {J. C.}",
year = "1990",
month = "1",
day = "1",
doi = "10.1093/ajcp/93.4.510",
language = "English (US)",
volume = "93",
pages = "510--515",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "4",

}

TY - JOUR

T1 - Experimental murine invasive pulmonary aspergillosis

AU - Eisenstein, D. J.

AU - Biddinger, Paul Williams

AU - Rhodes, J. C.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - A new model of invasive pulmonary aspergillosis (IPA) was developed in immunosuppressed mice. Intranasal route of inoculation was used to deliver predictable numbers of Aspergillus flavus conidia. The LD50 was determined to be 2.7 x 102 viable conidia, and a combination of quantitative culture and determination of chitin content was shown to best measure the progression of pulmonary disease. The evolution of IPA in these mice conformed with what has been reported in human cases of aspergillosis; both histopathology of the pulmonary lesions and dissemination pattern resembled their human counterparts. The authors hope to use this model to study virulence mechanisms of Aspergillus and novel therapeutic methods.

AB - A new model of invasive pulmonary aspergillosis (IPA) was developed in immunosuppressed mice. Intranasal route of inoculation was used to deliver predictable numbers of Aspergillus flavus conidia. The LD50 was determined to be 2.7 x 102 viable conidia, and a combination of quantitative culture and determination of chitin content was shown to best measure the progression of pulmonary disease. The evolution of IPA in these mice conformed with what has been reported in human cases of aspergillosis; both histopathology of the pulmonary lesions and dissemination pattern resembled their human counterparts. The authors hope to use this model to study virulence mechanisms of Aspergillus and novel therapeutic methods.

KW - Aspergillosis

KW - Histopathology

KW - Intranasal inoculations

KW - LD50

KW - Murine model

UR - http://www.scopus.com/inward/record.url?scp=0025360873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025360873&partnerID=8YFLogxK

U2 - 10.1093/ajcp/93.4.510

DO - 10.1093/ajcp/93.4.510

M3 - Article

C2 - 2321582

AN - SCOPUS:0025360873

VL - 93

SP - 510

EP - 515

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 4

ER -